Session » Poster Session 3

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Time: 4:15PM-5:15PM

Meeting: 2020 Pediatric Rheumatology Symposium

4:15PM-5:15PM: Abstract Number: 165

A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus

4:15PM-5:15PM: Abstract Number: 188

A New Multidisciplinary Pediatric SLE Clinic in a Large Urban Care Center: Feasibility, Patient Satisfaction, and Quality After One Year

4:15PM-5:15PM: Abstract Number: 184

A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents

4:15PM-5:15PM: Abstract Number: 119

Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database

4:15PM-5:15PM: Abstract Number: 186

Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases

4:15PM-5:15PM: Abstract Number: 145

Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA

4:15PM-5:15PM: Abstract Number: 163

Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies

4:15PM-5:15PM: Abstract Number: 130

Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis

4:15PM-5:15PM: Abstract Number: 115

Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study

4:15PM-5:15PM: Abstract Number: 160

CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis

4:15PM-5:15PM: Abstract Number: 120

Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years

4:15PM-5:15PM: Abstract Number: 148

Chronic Fatigue Symptoms in Children with Abrupt Early-onset OCD And/or PANS

4:15PM-5:15PM: Abstract Number: 132

Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit

4:15PM-5:15PM: Abstract Number: 183

Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship

4:15PM-5:15PM: Abstract Number: 126

Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience

4:15PM-5:15PM: Abstract Number: 141

Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review

4:15PM-5:15PM: Abstract Number: 127

Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus

4:15PM-5:15PM: Abstract Number: 121

Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis

4:15PM-5:15PM: Abstract Number: 113

Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease

4:15PM-5:15PM: Abstract Number: 134

Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus

4:15PM-5:15PM: Abstract Number: 193

Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE

4:15PM-5:15PM: Abstract Number: 168

Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity

4:15PM-5:15PM: Abstract Number: 144

Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis

4:15PM-5:15PM: Abstract Number: 147

Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD

4:15PM-5:15PM: Abstract Number: 117

Family Impact of Juvenile Localized Scleroderma

4:15PM-5:15PM: Abstract Number: 125

Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis

4:15PM-5:15PM: Abstract Number: 181

Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis

4:15PM-5:15PM: Abstract Number: 146

Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial

4:15PM-5:15PM: Abstract Number: 143

Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease

4:15PM-5:15PM: Abstract Number: 161

Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States

4:15PM-5:15PM: Abstract Number: 189

Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic

4:15PM-5:15PM: Abstract Number: 180

Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic

4:15PM-5:15PM: Abstract Number: 159

Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis

4:15PM-5:15PM: Abstract Number: 123

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis

4:15PM-5:15PM: Abstract Number: 167

Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment

4:15PM-5:15PM: Abstract Number: 118

Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers

4:15PM-5:15PM: Abstract Number: 137

Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

4:15PM-5:15PM: Abstract Number: 162

Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)

4:15PM-5:15PM: Abstract Number: 114

Musculoskeletal Ultrasound Study in Childhood Arthritis: A Limited Examination

4:15PM-5:15PM: Abstract Number: 182

Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood

4:15PM-5:15PM: Abstract Number: 179

New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network

4:15PM-5:15PM: Abstract Number: 139

Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

4:15PM-5:15PM: Abstract Number: 190

Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome

4:15PM-5:15PM: Abstract Number: 116

Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

4:15PM-5:15PM: Abstract Number: 133

Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting

4:15PM-5:15PM: Abstract Number: 187

Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings

4:15PM-5:15PM: Abstract Number: 185

pGALS Training Increases Canadian and Kenyan Physicians’ Confidence in Examining the Musculoskeletal System in Children

4:15PM-5:15PM: Abstract Number: 124

Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic

4:15PM-5:15PM: Abstract Number: 131

Practice Patterns for Consulting Pediatric Rheumatology in a Large Pediatric Intensive Care Unit

4:15PM-5:15PM: Abstract Number: 128

Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus

4:15PM-5:15PM: Abstract Number: 136

Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center

4:15PM-5:15PM: Abstract Number: 129

Reproductive Health Concerns in Young Adults with Pediatric Onset Rheumatic Diseases

4:15PM-5:15PM: Abstract Number: 166

Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones

4:15PM-5:15PM: Abstract Number: 138

Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

4:15PM-5:15PM: Abstract Number: 140

Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade

4:15PM-5:15PM: Abstract Number: 192

Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease

4:15PM-5:15PM: Abstract Number: 122

Systemic Inflammation and Cognitive Dysfunction in jSLE Patients

4:15PM-5:15PM: Abstract Number: 164

The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants

4:15PM-5:15PM: Abstract Number: 135

Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression

4:15PM-5:15PM: Abstract Number: 191

Utilization of Telemedicine in Pediatric Rheumatologic Care

4:15PM-5:15PM: Abstract Number: 142

WITHDRAWN

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].